CTSI’s Research Team Building Consultation Service

Sponsor:

NYU Langone Medical Center’s Clinical and Translation Science Institute

Deadline:

Rolling, but space is limited.

Summary:

The Research Team Building Consultation Service, funded through NYULMC’s CTSI mentoring program, was designed to help investigators at various stages (post docs through more senior investigators) build or enhance their team to improve research productivity while providing mentoring and training to the next generation of scholars, particularly those underrepresented in science. We help faculty/post docs build labs, design teams, and recruit over a 12-month period.

Eligibility:

No additional eligibility restrictions.

Available Funding:

Not applicable. The service will provide 15 hours of individual consultation for each investigator.

Link to Full RFP:

CTSI July 2017 Newsletter

Heineken Prizes 2018

Sponsor:

Dr H.P. Heineken Foundation and the Alfred Heineken Fondsen Foundation. The selection of the prizes is entrusted by the Royal Netherlands Academy of Arts and Sciences.

Deadline:

October 15, 2017

Summary:

The Heineken Prizes are intended explicitly for scientists and scholars who are currently active in their field and whose research still holds considerable promise for future innovative discoveries. International juries will select the winners.

Eligibility:

Prizes are available in the following fields:

Available Funding:

$200,000

Link to Full RFP:

http://www.knaw.nl/en/awards/awards/heinekenprizes/heinekenprijs-voor-de-milieuwetenschappen

Parkinson’s Research Program (PRP) – Investigator-Initiated Research Award (IIRA)

Sponsor:

U.S Department of Defense Congressionally Directed Medical Research Programs (CDMRP)

Deadline:

Pre-application: 5 PM EST, August 17, 2017

Application: 11:59 PM EST, August 31, 2017

Summary:

The PRP Investigator-Initiated Research Award (IIRA) mechanism is being offered for the first time in FY17. The PRP Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research and/or patient care. This award mechanism supports the full spectrum of research from basic science through clinical research that specifically focuses on scientific and clinical Parkinson’s disease issues, which, if successfully addressed, have the potential to make a major impact in understanding, preventing, diagnosing, or treating Parkinson’s disease or enhancing the well-being of individuals experiencing the impact of the disease.
Consistent with the mission of the FY17 PRP to support research to understand, prevent, diagnose, and treat Parkinson’s disease in patients, including Service members and Veterans, investigators are required to address at least one of the following FY17 PRP Focus Areas:
  1. Mechanisms of neuroplasticity in the Parkinson’s disease brain.
  2. Studies to identify gene-environment interactions in Parkinson’s disease cohorts (applications addressing this focus area have an additional submission requirement; please see RFP.
  3. Pathophysiological implications of tau protein in Parkinson’s disease.

Eligibility:

Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to submit an application as an Initiating or Partnering PI.
Preliminary data to support feasibility are encouraged. Any unpublished, preliminary data provided should originate from the laboratory of the PI or a member(s) of the research team. The preliminary data must support the feasibility of the study.
Partnering PI Option: The Investigator-Initiated Research Award mechanism includes an option for up to three PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) (maximum of two) will be identified as a Partnering PI(s). Initiating and Partnering PIs each have different submission requirements, please see full RFP.
Available Funding:
  • Single PI:  The anticipated total costs budgeted for the entire period of performance for an FY17 PRP IIRA will not exceed $1M.  The maximum period of performance is three (3) years.
  • Multi PI: The anticipated total costs budgeted for the entire period of performance for an FY17 PRP IIRA will not exceed $2.5M. The maximum period of performance is four (4) years.

Link to Full RFP:

http://cdmrp.army.mil/funding/pa/FY17-PRP-IIRA.pdf

Parkinson’s Research Program (PRP) – Early Investigator Research Award

Sponsor:

U.S Department of Defense Congressionally Directed Medical Research Programs (CDMRP)

Deadline:

Pre-application: 5 PM EST, August 17, 2017

Application: 11:59 PM EST, August 31, 2017

Summary:

The PRP Early Investigator Research Award (EIRA) mechanism is being offered for the first
time in FY17. The PRP Early Investigator Research Award supports Parkinson’s disease-focused research opportunities for individuals in the early stages of their careers, under the guidance of a designated Mentor.
Consistent with the mission of the FY17 PRP to support research to understand, prevent,
diagnose, and treat Parkinson’s disease in patients, including Service members and Veterans,
investigators are required to address at least one of the following FY17 PRP Focus Areas:
  1. Mechanisms of neuroplasticity in the Parkinson’s disease brain.
  2. Studies to identify gene-environment interactions in Parkinson’s disease cohorts (applications addressing this focus area have an additional submission requirement; please see RFP.
  3. Pathophysiological implications of tau protein in Parkinson’s disease.

 

Eligibility:

 The Early Investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of Parkinson’s disease research; however, the PI is not required to have previous Parkinson’s disease research experience. Clinical fellows applying to the PRP EIRA mechanism should be specializing in movement disorders.

The investigator must be a postdoctoral or clinical fellow within three years of advanced degree or residency training (or equivalent) as of the application deadline

Applications must include at least one Mentor, appropriate to the proposed research project, who has experience in Parkinson’s disease research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a Parkinson’s disease researcher.

Available Funding:

The anticipated total (direct plus indirect) costs budgeted for the entire period of performance will not exceed $321,000. The maximum period of performance is two (2) years. The PRP’s FY17 appropriation is $16M.

Link to Full RFP:

http://cdmrp.army.mil/funding/pa/FY17-PRP-EIRA.pdf

MSK Lymphoma SPORE 2017-2018 Career Enhancement Program (CEP) Awards

Sponsor:
Hosted at Memorial Sloan Kettering Cancer Center – Funded by the National Institutes of Health

Deadline:

July 28, 2017

Summary:

The aim of this RFA is to identify, train and/or develop talented individuals to become successful translational investigators in the field of lymphoma. The program will support 1 or 2 individuals per year for up to two years per awardee, based on competitive renewal. Awardees will be integrated into the SPORE in order to monitor their progress and ensure successful outcome of their research projects, and will be prepared to obtain independent peer-reviewed funding.

Eligibility:

Investigators at Memorial Sloan Kettering Cancer Center, Rockefeller University, Weill Cornell Medical Center, Columbia University, Mount Sinai Hospital, and NYU, are eligible.
Funds from this program may be used to support junior faculty or established investigators who wish to enhance or refocus their careers on translational research. Eligible candidates will include individuals with the following qualifications:
a) M.D. (or D.O), PhD, or MD/PhD degree. This program is not a training program and does not support pre- or post-doctoral fellows, either pre-clinical or clinical. However, advanced post-doctoral or clinical fellows who provide a letter from an institution stating that the candidate will be joining its faculty within the year are eligible for this program.
b) Commitment to a career path in translational lymphoma research. Candidates must have demonstrated a strong aptitude for and interest in biomedical research, as evidenced by experience in the laboratory or other relevant research.
c) Exceptional clinical candidates that do not currently have an active laboratory program may also apply, provided they have a strong scientific/laboratory background, and are working with a laboratory mentor who can provide them with the necessary guidance and resources to develop a hypothesis that can be tested in the clinical setting
d) Investigators supported by NCI career development awards (K series) may also be eligible for support through this program. Investigators with previous R01 or equivalent level of funding related to lymphoma translational research are not eligible

Anticipated Funding Amount:

The program will support 1 or 2 individuals per year for up to two years per awardee, based on competitive renewal. The maximum award will be $50,000 for one year. Applicants will be funded for a maximum of two years with funding for the second year contingent on documented significant progress during the first year of funding, and peer review evaluations.

PROPOSAL PROCESS:

Proposals cannot be currently funded by an extramural agency or foundation. The budget is limited to $50K/year (direct costs. No indirect costs). Proposals must be submitted to Felicia Reid reidf@mskcc.org by July 24th, 2017.

REQUIRED INFORMATION:

Research proposals must be no longer than 5 pages (excluding budget) and should follow the format for an R01 grant application; the length of the final proposal are limited to 6 pages. The proposals will require the following standard NIH format:
Format: Applications must be in 11-point Arial. Margins must be at least 0.50 inches wide on all sides of each page.
1) Face Page (including Title, Name of Applicant, and Names of Key Collaborators)
2) Abstract (250 words max)
3) Research Plan (5-page limit). Include the following content: Specific Aims, Preliminary Studies, and Research Strategy (a. Significance, b. Innovation, c. Approach)
4) Research environment (1 page)
5) Include up to 6 Literature Citations
6) Human Subjects or Vertebrate Animals. (Please follow the NIH guidelines)
7) NIH Biosketch for all key personnel (5 pages each in NIH-specified format)
8) Budget and Budget Justification. Include a detailed NIH-format Budget for one year totaling $50,000 direct costs. The application must include a detailed budget for the initial year, a summary budget, and a budget justification.
9) The application should include a statement of long-term career goals, letter of support from the mentor with the Mentor’s CV, and 3 letters of recommendation.
REVIEW CRITERIA:
Applications will be reviewed and scored by the CEP Committee, which is composed of a diverse pool of experienced individuals with laboratory and clinical expertise. The CEP Co-Directors will assign two reviewers from the CEP Committee (one primary and one secondary reviewer) for each proposal. The initial selection will be based on the following criteria:
1. Scientific merit of the proposed project
2. Innovation
3. Approach
4. Qualifications of the investigator
5. Qualifications of the mentor
6. Research environment
IRB approval (or waiver) will be required before funding if the study involves human subjects.
SCIENTIFIC REVIEW COMMITTEE:
The CEP Co-Directors will assign two reviewers from the CEP Committee (one primary and one secondary reviewer) for each proposal.
FUNDING CYCLES:
Awards will begin in August 2017
Authors must cite the MSK Lymphoma SPORE (P50 CA192937) in the funding acknowledgements when submitting a manuscript based on research supported, in whole or in part, by this SPORE-Career Enhancement Program.
Written progress and final reports will be required at the end of funding period. Any questions regarding this solicitation should be directed to Felicia Reid reidf@mskcc.org or to the CEP directors; Dr. Riccardo Dalla Favera rd10@cumc.columbia.edu or Dr. Andrew Zelenetz Zelenetz a-zelenetz@ski.mskcc.org.
KEY DATES:
• Applications are due on July 24th, 2017
• Award Announcements by August 18th, 2017
• Award Start Date: August 30th, 2017
SUBMISSION INFORMATION:
Proposals must be submitted electronically to Felicia Reid reidf@mskcc.org. Proposals must be submitted as a compiled PDF document.
ADDITIONAL BUDGET INFORMATION:
Up to $50K direct costs for one year, may be renewable for an additional year based on review
Expenditures allowed
1 Research supplies and animal maintenance.
2 Technical assistance.
3 Publication costs, including reprints.
4 Data analysis.
5 Special fees (pathology, photography, etc.).
6 Stipends for graduate students and postdoctoral fellows.
The following expenditures will not be considered:
1 Secretary or administrative personnel.
2 Office equipment or supplies.
3 Laboratory equipment or computers.
4 Tuition.
5 Foreign travel.
6 Honoraria and travel expenditures.
7 Recruitment.
8 Patient care charges (requires justification if a clinical trial is proposed).
9 Non-medical or personal services to patients

 

MSK Lymphoma SPORE 2017-2018 Developmental Research Program (DRP) Awards

Sponsor:
Hosted at Memorial Sloan Kettering Cancer Center – Funded by the National Institutes of Health

Deadline:

July 28, 2017

Summary:

This RFA is designed to support young investigators as well as established investigators focusing on basic, translational, or clinical research of lymphoma. The primary objective of this DRP Award is to support pilot projects that explore innovative ideas in basic and translational research in lymphoma. Potential topics of interest include, but are not limited to:
• Pathogenesis
• Experimental therapeutics, including mechanism based combinations, and biomarker driven treatment strategies
• Immunology and immunotherapies
• Circulating tumor DNA

Eligibility:

Investigators at Memorial Sloan Kettering Cancer Center, Rockefeller University, Weill Cornell Medical Center, Columbia University, Mount Sinai Hospital, and NYU, are eligible.
Applicants must hold academic rank of Instructor, Assistant Professor, or higher.
Applicants must possess an MD, DO or a PhD degree in a relevant area of research. The pilot projects may be collaborative among scientists within one or more SPOREs, or with scientists outside the SPORE community including the international scientific community. High risk/high payoff pilot projects are especially encouraged. These pilot projects do not need to reach a human endpoint during the project period as do full projects, including the Developmental Research Program. Letters of collaboration (if if applicable)

Proposals cannot be currently funded by an extramural agency or foundation. The budget is limited to $50K/year (direct costs. No indirect costs).

Anticipated Funding Amount:

Each year, 3-4 applications will be funded. The maximum award will be $50,000 for one year. Applicants will be funded for a maximum of two years with funding for the second year contingent on documented significant progress during the first year of funding, and peer review evaluations.

PROPOSAL PROCESS:

Proposals cannot be currently funded by an extramural agency or foundation. The budget is limited to $50K/year (direct costs. No indirect costs). Proposals must be submitted to Felicia Reid reidf@mskcc.org by July 24th, 2017.

REQUIRED INFORMATION:
Research proposals must be no longer than 5 pages (excluding budget) and should follow the format for an R01 grant application; the length of the final proposal are limited to 6 pages. The proposals will require the following standard NIH format:
Format: Applications must be in 11-point Arial. Margins must be at least 0.50 inches wide on all sides of each page.
MSK Lymphoma SPORE
2017-2018 Developmental Research Program (DRP) Awards
1) Face Page (including Title, Name of Applicant, and Names of Key Collaborators)
2) Abstract (250 words max)
3) Research Plan (5-page limit). Include the following content: Specific Aims, Preliminary Studies, and Research Strategy (a. Significance, b. Innovation, c. Approach)
6) Research environment (1 page)
7) Include up to 6 Literature Citations
8) Human Subjects or Vertebrate Animals. (Please follow the NIH guidelines)
9) NIH Biosketch for all key personnel (5 pages each in NIH-specified format)
10) Budget and Budget Justification. Include a detailed NIH-format Budget for one year totaling $50,000 direct costs. The application must include a detailed budget for the initial year, a summary budget, and a budget justification.
REVIEW CRITERIA:
All proposals will be reviewed by the scientific review committee and ad hoc reviewers, according to the following criteria, as relevant:
1. Scientific merit of the proposed project
2. Innovation
3. Approach
4. Qualifications of the investigator
5. Research environment
IRB approval (or waiver) will be required before funding if the study involves human subjects.
SCIENTIFIC REVIEW COMMITTEE:
The DRP Review Committee will include 3 ad hoc members of the SPORE Internal Advisory Board Committee, and 3 ad hoc members of the SPORE External Advisory Board Committee, and 3 additional external reviewers from other lymphoma SPORES
FUNDING CYCLES:
Awards will begin in August 2017
Authors must cite the MSK Lymphoma SPORE (P50 CA192937) in the funding acknowledgements when submitting a manuscript based on research supported, in whole or in part, by this SPORE-Developmental Research Program.
Written progress and final reports will be required at the end of funding period. Any questions regarding this solicitation should be directed to Felicia Reid reidf@mskcc.org or to the DRP directors; Dr. John Leonard jpleonar@med.cornell.edu or Dr. Anas Younes younesa@mskcc.org.
KEY DATES:
• Applications are due on July 24th, 2017
• Award Announcements by August 18th, 2017
• Award Start Date: August 30th, 2017

SUBMISSION INFORMATION:
Proposals must be submitted electronically to Felicia Reid reidf@mskcc.org. Proposals must be submitted as a compiled PDF document.
ADDITIONAL BUDGET INFORMATION: Up to $50K direct costs for one year, may be renewable for an additional year based on review
Expenditures allowed
1 Research supplies and animal maintenance.
2 Technical assistance.
3 Publication costs, including reprints.
4 Data analysis.
5 Special fees (pathology, photography, etc.).
6 Stipends for graduate students and postdoctoral fellows.
The following expenditures will not be considered:
1 Secretary or administrative personnel.
2 Office equipment or supplies.
3 Laboratory equipment or computers.
4 Tuition.
5 Foreign travel.
6 Honoraria and travel expenditures.
7 Recruitment.
8 Patient care charges (requires justification if a clinical trial is proposed).
9 Non-medical or personal services to patients.

SFARI Explorer Awards

Sponsor:

Simons Foundation Autism Research Initiative (SFARI)

Deadline:

Applications are considered on a rolling basis, with a response time as early as 30 days.

Summary:

This award program is designed to enhance our existing support of autism research by providing timely resources to enable focused experiments highly relevant to our mission. A deeper understanding of the mechanisms underlying autism spectrum disorders or potential therapeutic approaches will require investigation at multiple levels, including but not limited to studies focused on gene discovery, molecular mechanisms, circuits, anatomy, and cognition and behavior. We will consider proposals at all of these levels.

Explorer Awards are intended to provide resources to support exploratory experiments that will strengthen hypotheses and lead to the formulation of competitive applications for subsequent larger-scale funding by SFARI or other organizations. Innovative, high-risk/high-impact proposals are encouraged. We especially encourage applications from investigators who are new to the field of autism, but who have expertise that could be brought to bear on this complex disorder.

Eligibility:

All applicants and key collaborators must hold a Ph.D., M.D. or equivalent degree and have a faculty position or the equivalent at a college, university, medical school or other research facility. Applications may be submitted by domestic and foreign nonprofit organizations; public and private institutions, such as colleges, universities, hospitals, laboratories, units of state and local government; and eligible agencies of the federal government. There are no citizenship or country requirements.

Available Funding:

The maximum budget is $70,000, including indirect costs for one (1) year, non-renewable.

Link to Full RFP:

https://sfari.org/funding/grants/explorer-awards-rfa

SFARI Bridge to Independence Award Request for Applications

Sponsor:

Simons Foundation Autism Research Initiative (SFARI)

Deadline:

August 7, 2017

Summary:

The Simons Foundation Autism Research Initiative (SFARI) seeks to improve the understanding, diagnosis and treatment of autism spectrum disorders by funding innovative research of the highest quality and relevance.  In order to sustain this level of scientific excellence in future years, SFARI is extending our support to promising early-career investigators.

Grants awarded through the Bridge to Independence Award program are intended to invest in the next generation of top autism investigators by identifying talented early-career scientists interested in autism research and facilitating their transition to an independent research career. This request for applications (RFA) is aimed at senior postdoctoral fellows who intend to seek tenure-track faculty positions during the 2017–18 academic year. Successful applicants will be notified that they are finalists in the Bridge to Independence Award program and will have one year to submit an approval application, which includes confirmation of a tenure-track professorship at a U.S. academic institution, review of the institution’s research environment and resources, and institutional signoff.

Eligibility:

  • Applicants must hold a Ph.D., M.D. or equivalent degree
  • Applicants must have fewer than six (6) years of postdoctoral or otherwise mentored training.
  • Applicants must be currently in non-independent, mentored, training positions, as recognized by their institution. The following guidelines should be used to distinguish independent from non-independent positions (modified from NIH’s K99/R00 Program Announcement eligibility section): Evidence for non-independence may include:
  • The applicant’s research is entirely funded by another investigator’s grants.
  • The applicant’s research is conducted entirely in another investigator’s assigned space.
  • According to institutional policy, the applicant is not allowed to submit an application for an NIH research grant (e.g., R01) or SFARI grant (e.g, Explorer, Pilot, Research, and Targeted awards.)
  • Applicants must be actively seeking a tenure-track position at a U.S. institution of higher education during 2017-18 academic year.
  • Applicants are not eligible if they are recipients of other career development awards with similar budgetary scope as the SFARI Bridge to Independence award. These include, but are not limited to:
    • NIH K99/R00 (please note that other K awardees may be eligible, e.g., K01 and K08)
    • Burroughs-Wellcome Fund Career Award for Medical Scientists
    • American Academy of Neurology Career Development Award
    • Howard Hughes Medical Institute Hanna H. Gray fellowship

You are strongly encouraged to contact SFARI prior to grant submission if you believe your career development award is comparable to the BTI award but is not listed above.

  • Applicants must not have accepted a formal offer for a tenure-track faculty position.
  • There are no citizenship requirements.

Available Funding:

The principal investigator (PI) will receive research support at a fixed rate of $150,000 per year, including 20 percent for indirect costs (see SFARI policies), for up to three (3) years. Funds may not be used toward the PI’s salary but may provide salary support for other laboratory personnel. Institutional start-up packages may not be reduced because of SFARI funding.

Link to Full RFP:

https://sfari.org/funding/grants/bridge-to-independence-rfa/bridge-to-independence-award-request-for-applications

Multi-discipline and Systemic Caring for the Woman Experiencing Menopause: Innovative Decision Making Tools

Sponsor:

Pfizer Independent Grants for Learning & Change

Deadline:

July 12, 2017

Summary:

Pfizer Global Medical Grants seeks to support innovative educational programming to support optimal and/or appropriate practice interventions regarding care and treatment of women experiencing menopause. Projects should focus on educational resources (e.g. patient-physician shared decision-making tools /innovative apps) to support effective identification of the need for therapeutic intervention and appropriate selection of therapeutic intervention based on presentation.

  • The learning and change strategy should address helping improve the care of women with menopause by:
  • Improving symptom identification (by patients or physicians)
  • Improving care systems that showcase and operationalize the wellness visit as a focus for menopausal care

Innovating patient-physician awareness of various treatment options and modalities for appropriate patients and with appropriate risk-balance assessment The educational initiative should be focused on primary care practitioners, nurse practitioners, physician assistants, obstetricians and gynecologists, and all other specialists who care for the menopausal woman. Proposals whose educational model is broadly applicable for use in other settings and/or used for resident education will be rated favorably.

In addition, proposals that include the following elements are of interest:

  • Completed within a 12 month timeframe
  • Developing durable tools, materials (e.g. >1 one time use)
  • Intraprofessional collaboration among organizations
  • Incorporating the patient perspective
  • Innovative in terms of approach and output
  • Robust outcomes plan that reflects optimization of care metrics

The utilization of multiple forms of innovation, such as digital communication or social media, to reach the intended audience and to measure change in comprehension and intent to apply learning in practice are critical parts of a successful grant.

Projects that focus on live annual meetings, regional conferences, and speaker series are out of scope.

Eligibility:

Project  must be based in the United States.

The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.

Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations, or even different disciplines are encouraged. All partners must have a relevant role, and the requesting organization must have a leadership role.

Available Funding:

Individual projects requesting up to $200,000 will be considered.

Link to Full RFP:

http://www.pfizer.com/files/IGLC_CGA17WH2_MenopausalCare.v.2.pdf

Addressing Attitudes, Beliefs, and Cultural Barriers in Women’s Health Decision-Making

Sponsor:

Pfizer Independent Grants for Learning & Change (IGLC)

Deadline:

July 26, 2017

Summary:

Pfizer Global Medical Grants seeks to support innovative educational programming to understand the role of patient attitudes, beliefs, and cultural barriers in women’s health decision-making during reproductive and post-reproductive health care. These factors have a major influence and variations exist globally for women during life events including family planning and menopause related issues. The learning and change strategy should address techniques to overcome barriers in improving the care of women during family planning and/or menopause by:

  • Improving care systems that showcase and operationalize the wellness visit
  • Innovating the patient-physician dialogue (e.g. ‘difficult conversations’)
  • Innovating patient-physician awareness of various treatment options and modalities for appropriate patients and with appropriate risk-balance assessment
  • Dispelling common patient myths and misconceptions.

The educational initiative should be focused on primary care practitioners including general practitioners, nurse practitioners, physician assistants, obstetricians and gynecologists, and/or other specialists who care for women in the reproductive phase of their lives, menopausal women, or all. Proposals whose educational model is broadly applicable for use in varied settings and/or used for trainee education will be rated favorably.

The utilization of multiple forms of innovation, such as digital communication or social media, to reach the intended audience and to measure change in comprehension and intent to apply learning in practice are critical parts of a successful grant.  

Eligibility:

Project must be global in scope.

The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.

Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations, or even different disciplines are encouraged. All partners must have a relevant role, and the requesting organization must have a leadership role.

Available Funding:

Individual projects requesting up to $200,000 will be considered.

Link to Full RFP:

http://www.pfizer.com/files/IGLC_CGA17WH1_WomensHealth.v.2.pdf